Tags

Type your tag names separated by a space and hit enter

Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial.
Eur J Clin Nutr 2017; 71(2):203-205EJ

Abstract

BACKGROUND/OBJECTIVES

Vitamin D insufficiency in cystic fibrosis is common. Vitamin D3 is currently preferred over D2. We aimed to study the efficacy of vitamin D2 and D3 at increasing serum 25-hydroxyvitamin D (s25OHD) concentrations and their effect on respiratory health in cystic fibrosis.

SUBJECTS/METHODS

Sixteen CF patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (<16 years old) or 7143 IU/day (⩾16 years old) was further individually adjusted. Three months of intervention were followed by two of washout (ClinicalTrials.gov NCT01321905).

RESULTS

To increase s25OHD, the mean daily dose of vitamin D2 and D3 had to be increased up to 15650 and 8184 IU, respectively. The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Patients provided vitamin D3 improved FVC at the end of the trial (P<0.05). Change in s25OHD was positively correlated with changes in the adult Quality-of-Life respiratory score at the end of supplementation (P=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout.

CONCLUSIONS

Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF.

Authors+Show Affiliations

Stockholm CF Center, Karolinska University Hospital Huddinge, Stockholm, Sweden. Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.Stockholm CF Center, Karolinska University Hospital Huddinge, Stockholm, Sweden. Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27966575

Citation

Pincikova, T, et al. "Clinical Impact of Vitamin D Treatment in Cystic Fibrosis: a Pilot Randomized, Controlled Trial." European Journal of Clinical Nutrition, vol. 71, no. 2, 2017, pp. 203-205.
Pincikova T, Paquin-Proulx D, Sandberg JK, et al. Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. Eur J Clin Nutr. 2017;71(2):203-205.
Pincikova, T., Paquin-Proulx, D., Sandberg, J. K., Flodström-Tullberg, M., & Hjelte, L. (2017). Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. European Journal of Clinical Nutrition, 71(2), pp. 203-205. doi:10.1038/ejcn.2016.259.
Pincikova T, et al. Clinical Impact of Vitamin D Treatment in Cystic Fibrosis: a Pilot Randomized, Controlled Trial. Eur J Clin Nutr. 2017;71(2):203-205. PubMed PMID: 27966575.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. AU - Pincikova,T, AU - Paquin-Proulx,D, AU - Sandberg,J K, AU - Flodström-Tullberg,M, AU - Hjelte,L, Y1 - 2016/12/14/ PY - 2016/04/07/received PY - 2016/10/24/revised PY - 2016/10/26/accepted PY - 2016/12/15/pubmed PY - 2018/1/11/medline PY - 2016/12/15/entrez SP - 203 EP - 205 JF - European journal of clinical nutrition JO - Eur J Clin Nutr VL - 71 IS - 2 N2 - BACKGROUND/OBJECTIVES: Vitamin D insufficiency in cystic fibrosis is common. Vitamin D3 is currently preferred over D2. We aimed to study the efficacy of vitamin D2 and D3 at increasing serum 25-hydroxyvitamin D (s25OHD) concentrations and their effect on respiratory health in cystic fibrosis. SUBJECTS/METHODS: Sixteen CF patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (<16 years old) or 7143 IU/day (⩾16 years old) was further individually adjusted. Three months of intervention were followed by two of washout (ClinicalTrials.gov NCT01321905). RESULTS: To increase s25OHD, the mean daily dose of vitamin D2 and D3 had to be increased up to 15650 and 8184 IU, respectively. The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Patients provided vitamin D3 improved FVC at the end of the trial (P<0.05). Change in s25OHD was positively correlated with changes in the adult Quality-of-Life respiratory score at the end of supplementation (P=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout. CONCLUSIONS: Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF. SN - 1476-5640 UR - https://www.unboundmedicine.com/medline/citation/27966575/Clinical_impact_of_vitamin_D_treatment_in_cystic_fibrosis:_a_pilot_randomized_controlled_trial_ L2 - http://dx.doi.org/10.1038/ejcn.2016.259 DB - PRIME DP - Unbound Medicine ER -